{"entity":{"id":"valentin-ortiz-maldonado","kind":"person","name":"Valentín Ortiz-Maldonado","aka":["Valentín Ortíz-Maldonado","V Ortiz-Maldonado"],"tldr":"Barcelona haematologist who led the clinical reports of ARI-0001, the hospital's own CD19 CAR-T, from the first trial to its use in mantle cell lymphoma.","summary":"Valentín Ortiz-Maldonado is a haematologist at Hospital Clínic de Barcelona and FRCB-IDIBAPS, according to the affiliation on his 2026 HemaSphere paper. He is first author of the 2021 Molecular Therapy report of CART19-BE-01, in which 47 of 58 included patients were treated with ARI-0001 and fractionated dosing cut grade 3 or higher cytokine release syndrome in acute lymphoblastic leukaemia from 26.7% to 4.3%, and senior author of the 2026 report on varnimcabtagene autoleucel in relapsed or refractory mantle cell lymphoma, where overall response among 27 infused patients was 89%. He also first-authored the ARI-0001 reports in leukaemia with isolated extramedullary disease and in chronic lymphocytic leukaemia.","asOf":"2026-11-03","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ortiz-Maldonado%20V%5BAuthor%5D"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Haematologist, Department of Hematology, Hospital Clínic de Barcelona and FRCB-IDIBAPS; Universitat de Barcelona","institutionId":"hospital-clinic-barcelona","specialisms":["CAR-T cell therapy","Acute lymphoblastic leukaemia","Lymphoma"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ortiz-Maldonado%20V%5BAuthor%5D"}],"papers":[{"title":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","journal":"Molecular Therapy","year":2021,"doi":"10.1016/j.ymthe.2020.09.027"},{"title":"Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma","journal":"HemaSphere","year":2026,"doi":"10.1002/hem3.70388"},{"title":"Results of ARI-0001 CART19 cell therapy in patients with relapsed/refractory CD19-positive acute lymphoblastic leukemia with isolated extramedullary disease","journal":"American Journal of Hematology","year":2022,"doi":"10.1002/ajh.26519"}]},"route":"/people/valentin-ortiz-maldonado/","neighbours":{"institution":[{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","route":"/institutions/hospital-clinic-barcelona/"}],"trial":[{"id":"cart19-be-01","kind":"trial","name":"CART19-BE-01 (ARI-0001 CAR-T, Hospital Clínic de Barcelona)","route":"/trials/cart19-be-01/"}],"paper":[{"id":"paper-cart19-be-01-mol-ther-2021","kind":"paper","name":"CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies","route":"/key-papers/paper-cart19-be-01-mol-ther-2021/"}]}}